Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ATTR
Pharma
AZ's $80B revenue target 'very much within reach,' CFO says
AZ's oncology chief suggested the PD-L1 inhibitor Imfinzi will likely be the company's largest oncology medicine by sales “in the midterm period.”
Angus Liu
Jan 14, 2026 10:00am
Pfizer's challenge of BridgeBio ads referred to federal agencies
Nov 10, 2025 11:15am
Alnylam's ATTR-CM launch blows past estimates again
Oct 30, 2025 8:00am
Pfizer to discontinue low-dose ATTR drug Vyndaqel in US in 2025
Aug 29, 2025 10:40am
Alnylam's market cap jumps past $50B
Aug 1, 2025 7:39am
BridgeBio's Attruby has 'found a place' in ATTR-CM market: CEO
Apr 30, 2025 8:46am
